Entasis Therapeutics Holdings Inc. (ETTX) Financial Analysis & Valuation | Quarter Chart
Entasis Therapeutics Holdings Inc. (ETTX)
ETTXPrice: $2.19
Fair Value: 🔒
🔒score
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-dur... more
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the disco... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Manoussos Perros |
| IPO Date | 2018-09-26 | CAGR | — |
| Employees | 51 | Website | www.entasistx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ETTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $74.79M | P/E Ratio | -1.95 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 3.32 |
| P/CF Ratio | -2.41 | P/FCF Ratio | — |
| EPS | $-1.12 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -1.13% | ROA | -1.15% |
| ROCE | -1.51% | Current Ratio | 4.1 |
| Quick Ratio | 4.1 | Cash Ratio | 3.33 |
| Debt/Equity | — | Interest Coverage | — |
| Altman Z Score | — | Piotroski Score | — |